辛妥珠单抗治疗原发性硬化性胆管炎:2期研究结果及对疾病自然史的启示
这项2期随机对照研究将234例代偿期原发性硬化性胆管炎(PSC)患者按1:1:1随机分配接受辛妥珠单抗75 mg、125 mg或安慰剂每周皮下注射96周。主要终点肝胶原含量变化在辛妥珠单抗75 mg组为-0.5%(vs 安慰剂 P=0.73)、125 mg组为+0.5%(vs 安慰剂 P=0.33)、安慰剂组为0.0,两剂量均未显著改善Ishak纤维化分期、肝硬化进展或临床事件频率。结论:辛妥珠单抗治疗96周未给PSC患者带来临床获益。
要点
- 辛妥珠单抗75 mg组肝胶原含量变化-0.5%(vs 安慰剂 P=0.73),125 mg组+0.5%(vs 安慰剂 P=0.33),安慰剂组0.0。
- 两剂量辛妥珠单抗较安慰剂均未显著降低Ishak纤维化分期、肝硬化进展或临床事件频率。
- 总体80例(34%)患者纤维化进展,47例(20%)发生PSC相关临床事件。
核心结论
- 使用LOXL2抑制剂辛妥珠单抗治疗96周未给PSC患者带来临床获益。
研究设计与样本
- 2期随机对照研究,将代偿期PSC肝病患者按1:1:1随机分配接受辛妥珠单抗75 mg、125 mg或安慰剂每周皮下注射96周。
- 共234例患者被随机分组并开始治疗。
主要发现
- 第96周时肝胶原含量较基线的平均变化:辛妥珠单抗75 mg组为-0.5%(vs 安慰剂 P=0.73),125 mg组为+0.5%(vs 安慰剂 P=0.33),安慰剂组为0.0。
- 与安慰剂相比,两剂量辛妥珠单抗均未显著降低Ishak纤维化分期、肝硬化进展或临床事件频率。
- 总体80例(34%)患者纤维化进展,47例(20%)发生PSC相关临床事件。
- 基线因素多变量模型中,PSC相关临床事件在晚期纤维化患者中更频繁(HR 2.03;95%CI 1.02-4.06;P=0.045),碱性磷酸酶更高者更频繁(每10 U/L HR 1.01;95%CI 1.00-1.02;P=0.015),增强肝纤维化评分更高者更频繁(每单位 HR 1.26;95%CI 0.98-1.61;P=0.073)。
- 总体不良事件和实验室异常发生率在各组间相似。
关键数值与推荐
- 主要疗效终点为基线至第96周经形态计量学评估的肝胶原含量平均变化。
- 其他终点包括Ishak纤维化分期变化和PSC相关临床事件频率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lysyl oxidase like-2 (LOXL2) plays a central role in fibrogenesis and is elevated in the serum and liver of patients with primary sclerosing cholangitis (PSC). We evaluated the safety and efficacy of simtuzumab, a monoclonal antibody directed against LOXL2, in patients with PSC. Patients with compensated liver disease caused by PSC were randomized 1:1:1 to receive weekly subcutaneous injections of simtuzumab 75 mg, simtuzumab 125 mg, or placebo for 96 weeks. The primary efficacy endpoint was mean change in hepatic collagen content assessed by morphometry between baseline and week 96. Additional endpoints included change in Ishak fibrosis stage and the frequency of PSC-related clinical events. Overall, 234 patients were randomized and started treatment. At week 96, the mean change from baseline in hepatic collagen content was -0.5% for patients receiving simtuzumab 75 mg (P = 0.73 versus placebo), +0.5% for patients receiving simtuzumab 125 mg (P = 0.33 versus placebo), and 0.0 for patients receiving placebo. Compared with placebo, neither dose of simtuzumab led to significant reductions in Ishak fibrosis stage, progression to cirrhosis, or frequency of clinical events. Overall, 80 (34%) patients had fibrosis progression and 47 (20%) experienced PSC-related clinical events. In a multivariate model of baseline factors, PSC-related clinical events were more frequent in patients with advanced fibrosis (hazard ratio [HR], 2.03; 95% confidence interval [CI], 1.02-4.06; P = 0.045), higher alkaline phosphatase (HR per 10 U/L, 1.01; 95% CI, 1.00-1.02; P = 0.015), and higher enhanced liver fibrosis score (HR per unit, 1.26; 95% CI, 0.98-1.61; P = 0.073). Overall, rates of adverse events and laboratory abnormalities were similar between groups. Conclusion: Treatment with the LOXL2 inhibitor simtuzumab for 96 weeks did not provide clinical benefit in patients with PSC.
引用
- Muir AJ, Levy C, Janssen HLA, et al. Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. Hepatology. 2019. PMID: 30153359. doi:10.1002/hep.30237
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。